Stockreport

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad Oncology SA - American Depositary Shares  (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors
PDF MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focu [Read more]